Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acinetobacter baumannii outer membrane proteins (OMPs) are a diverse group of proteins located in the outer leaflet of the Gram-negative bacterial cell wall, essential for maintaining structural integrity and mediating environmental interactions. These proteins, including major porins like OmpA and CarO, function as channels for nutrient acquisition and are critical virulence factors that facilitate adhesion to host tissues and the development of protective biofilms (Gaddy et al., 2009, PMID: 19139237). OMPs also serve as the primary gateway for many antibiotic classes, such as carbapenems; consequently, the loss or modification of these proteins is a hallmark of multi-drug resistance in clinical settings (Mussi et al., 2005, PMID: 15659488). Specific OMPs like BauA are involved in high-affinity iron uptake systems, which have been successfully exploited by 'Trojan horse' antibiotics like cefiderocol to bypass traditional resistance mechanisms (Shizuchi et al., 2022, PMID: 35194044). Due to their surface exposure and essential roles in bacterial survival, OMPs are currently being targeted for the development of novel small-molecule inhibitors, monoclonal antibodies, and vaccine candidates aimed at treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections (Lee et al., 2017, PMID: 28438973).
Drugs interact with these proteins either by utilizing them as entry portals (e.g., carbapenems entering through CarO), exploiting them for active transport via 'Trojan horse' mechanisms (e.g., cefiderocol binding to the iron-siderophore receptor BauA), or by binding to and disrupting the outer membrane stability (e.g., polymyxins interacting with the OMP-LPS complex).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acinetobacter baumannii outer membrane protein (OMP).